Difference between revisions of "Ketorolac"
From WikiAnesthesia
(Updated blank article) |
Chris Rishel (talk | contribs) m Tag: 2017 source edit |
||
| Line 11: | Line 11: | ||
| time_onset = 10-15 minutes | | time_onset = 10-15 minutes | ||
| duration = 2-4 hours | | duration = 2-4 hours | ||
}} | }}'''Ketorolac''' is a Non-Steroidal Anti-Inflammatory Drug (NSAID) that is frequently used intra-op for management of post-op pain. | ||
Ketorolac is a Non-Steroidal Anti-Inflammatory Drug (NSAID) that is frequently used intra-op for management of post-op pain. | |||
== Uses<!-- Describe uses of the drug. If appropriate, add subsections for each indication. --> == | == Uses<!-- Describe uses of the drug. If appropriate, add subsections for each indication. --> == | ||
* Post-op pain management | * Post-op pain management | ||
| Line 22: | Line 19: | ||
=== Absolute contraindications<!-- List absolute contraindications for use of the drug. If none, this section may be removed. --> === | === Absolute contraindications<!-- List absolute contraindications for use of the drug. If none, this section may be removed. --> === | ||
* GFR < 30mL/min | * GFR < 30mL/min | ||
=== Precautions<!-- List precautions for use of the drug. If none, this section may be removed. --> === | === Precautions<!-- List precautions for use of the drug. If none, this section may be removed. --> === | ||
* Chronic renal disease | * Chronic renal disease | ||
* AKI | * AKI | ||
| Line 37: | Line 32: | ||
==== Mechanism of action<!-- Describe the mechanism of action for the primary uses of the drug. --> ==== | ==== Mechanism of action<!-- Describe the mechanism of action for the primary uses of the drug. --> ==== | ||
* NSAID that inhibits COX | * NSAID that inhibits COX | ||
* Of the NSAIDs, most selective for COX-1 inhibition over COX-2 | * Of the NSAIDs, most selective for COX-1 inhibition over COX-2 | ||
==== Adverse effects<!-- Describe any potential adverse effects of the drug. --> ==== | ==== Adverse effects<!-- Describe any potential adverse effects of the drug. --> ==== | ||
* COX-1 selectivity increases risk for GI tract irritation and bleeding | * COX-1 selectivity increases risk for GI tract irritation and bleeding | ||
* Thromboembolic disease is always a consideration when using NSAIDs, although ketorolac has lower risk for exacerbating thromboembolic disease compared to more COX-2 selective agents like celecoxib | * Thromboembolic disease is always a consideration when using NSAIDs, although ketorolac has lower risk for exacerbating thromboembolic disease compared to more COX-2 selective agents like celecoxib | ||
=== Pharmacokinetics<!-- Describe the pharmacokinetics of the drug. --> === | === Pharmacokinetics<!-- Describe the pharmacokinetics of the drug. --> === | ||
* Highly protein bound | * Highly protein bound | ||
* Almost completely renally eliminated | * Almost completely renally eliminated | ||
Latest revision as of 23:13, 23 February 2024
Ketorolac
| Trade names |
Toradol |
|---|---|
| Clinical data | |
| Drug class |
NSAID |
| Uses |
Post-op pain |
| Contraindications |
Renal disease or injury, peptic ulcer disease, GI bleeding |
| Routes of administration |
IV, IM, oral |
| Dosage |
IV or IM: 30mg once, if needed can repeat q6h up to 120mg daily |
| Dosage | |
|
A 10 mg dose of ketorolac is as effective for acute pain control as a 15 or 30 mg dose1
|
|
| Pharmacodynamics | |
| Mechanism of action |
Inhibition of COX (COX-1 > COX-2) |
| Pharmacokinetics | |
| Onset of action |
10-15 minutes |
| Duration of action |
2-4 hours |
| Physical and chemical data | |
| Article quality | |
| Editor rating | |
| User likes | 0 |
Ketorolac is a Non-Steroidal Anti-Inflammatory Drug (NSAID) that is frequently used intra-op for management of post-op pain.
Uses
- Post-op pain management
Contraindications
Absolute contraindications
- GFR < 30mL/min
Precautions
- Chronic renal disease
- AKI
- GI bleeding
- Peptic ulcer disease
Pharmacology
Pharmacodynamics
Mechanism of action
- NSAID that inhibits COX
- Of the NSAIDs, most selective for COX-1 inhibition over COX-2
Adverse effects
- COX-1 selectivity increases risk for GI tract irritation and bleeding
- Thromboembolic disease is always a consideration when using NSAIDs, although ketorolac has lower risk for exacerbating thromboembolic disease compared to more COX-2 selective agents like celecoxib
Pharmacokinetics
- Highly protein bound
- Almost completely renally eliminated
Chemistry and formulation
History
References
- ↑ Toda C, Naguib M. Peripherally acting analgesics. In: Flood P, Rathmell JP, and Urman RD (eds). Stoelting’s Pharmacology & Physiology in Anesthetic Practice. Sixth edition. Philadelphia, Pennsylvania; Wolters Kluwer; 2022: 257-65.
- ↑ "Nonsteroidal Anti-inflammatory Drugs".
- ↑ Colvin L. Physiology and pharmacology of pain. In: Thompson, JP, Moppett IK, and Wiles M (eds). Smith and Aitkenhead’s Textbook of Anaesthesia. 7th ed. Edinburgh; Elsevier; 2019: 99-120.
- ↑ Aronson JK. Non-steroidal anti-inflammatory drugs. In: Aronson, JK. Meyler’s Side Effects of Drugs: the International Encyclopedia of Adverse Drug Reactions and Interactions. Sixteenth edition. Amsterdam, Netherlands; Elsevier; 2016: 236-72.
- ↑ Hurley R, Elkassabany NM, Wu CL. Acute postoperative pain. In: Miller’s Anesthesia. 9th ed. Philadelphia; Elsevier; 2020:2620-22.
- ↑ Mahmoodi, Ahmad N.; Kim, Peggy Y. (2024), "Ketorolac", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 31424756, retrieved 2024-02-14
- ↑ Buckley, Micaela M.-T.; Brogden, Rex N. (1990-01-01). "Ketorolac". Drugs. 39 (1): 86–109. doi:10.2165/00003495-199039010-00008. ISSN 1179-1950.
Top contributors: Sean Liu, Olivia Sutton and Chris Rishel